...

CCO Treatment Updates

Master Class on Evolving Evidence and Emerging Treatments: Targeted Agents in Advanced Renal Cell Carcinoma

Interactive Virtual Presentation

Master Class on Evolving Evidence and Emerging Treatments: Targeted Agents in Advanced Renal Cell Carcinoma

Faculty:

Brian I. Rini, MD
  • Brian I. Rini, MD

CREDIT INFORMATION

Release Date: 05/18/09

Expiration Date: 05/17/10


Physicians: maximum of 0.75 AMA PRA Category 1 Credits

Status: Please log in to view status

Begin the Virtual Presentation

Brian I. Rini, MD, discusses current thinking regarding the use of targeted agents in the treatment of kidney cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guidelines for the treatment of renal cell carcinoma
  • Discuss the use of nephrectomy in the treatment of patients with renal cell carcinoma
  • Compare recent clinical trial data regarding first-line treatment of renal cell carcinoma
  • Describe recent studies of second-line therapies, including targeted agents and combination regimens, for the treatment of renal cell carcinoma
  • List patient-specific factors that guide therapy decisions in the setting of renal cell carcinoma

Slideset: Master Class on Evolving Evidence and Emerging Treatments: Targeted Agents in Advanced Renal Cell Carcinoma

Download the Slideset


Download a presentation by Brian I. Rini, MD, in which he recaps the discussions from a Master Class Symposium on current treatment strategies in RCC.


Format: Microsoft PowerPoint (.ppt) | File size: 3.12 MB | Date posted: 5/18/2009


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.